2142.HK Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (13 May 2024 @ 04:08):

HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas...

Stats
Today's Volume	3.08M
Average Volume	1.49M
Market Cap	1.09B
EPS	HKD0 ( 2024-03-27 )
Next earnings date	( HKD0 ) 2024-06-06
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	6.17
ATR14	HKD0.00500 (0.35%)

Volume Correlation

Long: -0.26 (neutral)

Short: 0.50 (neutral)

Signal:(47.016) Neutral

HBM Holdings Limited Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

HBM Holdings Limited Correlation - Currency/Commodity

0.31
( neutral )

0.08
( neutral )

0.00
( neutral )

-0.47
( neutral )

HBM Holdings Limited Financials

Annual	2023
Revenue:	HKD89.50M
Gross Profit:	HKD87.47M (97.73 %)
EPS:	HKD0.0300

FY	2023
Revenue:	HKD89.50M
Gross Profit:	HKD87.47M (97.73 %)
EPS:	HKD0.0300

FY	2022
Revenue:	HKD40.66M
Gross Profit:	HKD40.53M (99.68 %)
EPS:	HKD-0.190

FY	2021
Revenue:	HKD4.31M
Gross Profit:	HKD4.17M (96.82 %)
EPS:	HKD-0.179

Financial Reports:

No articles found.

HBM Holdings Limited

HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; Tanfanercept (HBM9036) to treat moderate to-severe dry eye disease; HBM7008, a bispecific antibody targeting tumor Associated antigen; and HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4. The company is also developing HBM9022 for the treatment of SARS-COV-2; HBM9302 for the treatment of breast and gastric cancers; HBM7020 for the treatment of multiple myeloma; and HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022 for the treatment of solid tumors. It operates in Mainland China, the United States, Europe, and internationally. The company has collaboration on antibody-drug conjugate projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was incorporated in 2016 and is based in Shanghai, the People's Republic of China.